The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
Oncoscape, an open-source data tool developed at Fred Hutchinson Cancer Research Center, will soon be able to produce 3D exome visualizations on commercial VR headsets.
A modified version of a commercially available magnetic bead cell sorting instrument from Miltenyi Biotec could be deployed to areas without cGMP facilities.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
Fred Hutch researchers report that analysis of one metastatic prostate tumor sample captures most of the variation in an individual's various metastases.
